Skip to main content
Premium Trial:

Request an Annual Quote

Azra AI Partners With Massive Bio to Bring Clinical Trial Matching to its Platform

NEW YORK – Health technology firms Massive Bio and Azra AI on Thursday announced a partnership to add Massive's clinical trial matching capabilities to Azra's cancer identification platform.

Azra's technology is used in more than 200 hospitals, the companies said in the announcement, to help clinicians more quickly process pathology reports and classify cancers and identify treatment for cancer patients faster. Azra's system will now also send patient data to Massive's platform to serve oncologists with information about relevant clinical trials.

"We are eager to partner with Massive Bio to connect these two parts of the cancer journey," Azra AI CEO Chris Cashwell said in a statement. "We can revolutionize the clinical trial process by automating the identification of potential patients early on using artificial intelligence. We are combing through millions of pathology reports and identifying cancer types more quickly. The data sent to Massive Bio's platform closes the loop on serving that patient the best treatment options for their cancer."

This month, Massive also announced a partnership with to combine its clinical trial matching with Perthera's technology that interprets multiomic testing results and matches patients to targeted therapies.